Asbestos Related Diseases
The Victims of a Stealthy Killer
The first generation of asbestos victims in northeast Ohio was shipbuilders, pipefitters and construction workers. Its latest generation comes from all walks of life. More…
The Cruel Saga of Asbestos Disease
The renowned epidemiologist Dr. Irving J. Selikoff was known to say that studying asbestos disease was like throwing a rock into a pond and seeing how far the ripples extended outward. More…
Asbestos Diseases Wait to Attack
In 1983, as a teenage dad, Tony Coleman worked six dusty days a week as a mechanic in South Euclid. Not even taking time to change clothes after work, Coleman raced home to his girlfriend, where their baby greeted him, chubby arms raised. The new dad gathered him up like a flower. More…
Asbestosis
ATS Posts New Guidelines for Diagnosing Asbestosis
The American Thoracic Society (ATS) updated the 1986 criteria for diagnosing and treating patients with nonmalignant disease related to asbestos, according to a report in the Sept. 15 issue of the American Journal of Respiratory and Critical Care Medicine. These conditions include asbestosis, pleural thickening or asbestos-related pleural fibrosis (plaques or diffuse fibrosis), "benign" (nonmalignant) pleural effusion, and airflow obstruction. More…
Asbestosis Research: Of Interest
Doctors in Iowa City, Iowa have concluded that patients with pleural scarring only that is caused by asbestos suffer from decreased gas exchange in the lungs during maximum exercise. Asbestos companies will argue at trial that plaintiffs with pleural disease only, as opposed to internal scarring of the lung, do not have any impairment or compensable Injury. More…
Non-small-cell-lung cancer
Non-small cell lung cancer (NSCLC) usually takes years to develop. Patients at an early stage usually do not have any symptoms and abnormalities cannot easily be detected through X-Ray. Usually NSCLC starts in the lining of the bronchi tubes leading into the lungs but as the cancer develops, tumors can metastasize elsewhere. More…
Lung Cancer Screening: Lungcheck
I was reviewing your web site and am truly impressed at the compassion you exude to asbestos victims and the passion with which you protect their rights. Please review the information below. I believe that LungCheck can help you and your clients. More…
Update on Non-Small Cell Lung Cancer Treatments & Trials
Novel HER1/EGFR-Targeted Agents for Non-Small Cell Lung Cancer: Current State of the Art. More…
Alimta (pemetrexed) in Patients with Non-Small Cell Lung Cancer
It is possible that information collected during this study will be analyzed by the Sponsor in the future to evaluate ALIMTA for other possible uses or for other medical or scientific purposes other than those currently proposed. Although ALIMTA has been shown to be effective in some patients with non-small-cell lung cancer, ALIMTA might not have beneficial effects for all patients. More…
NSCLC - FDA endorses Eli Lilly cancer drug Alimta (pemetrexed)
The Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration positively endorsed Alimta? (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer. More…
BAY 43-9006 in Treating Patients With Refractory Non-Small Cell Lung Cancer
BAY 43-9006 is a "targeted drug" specifically engineered to inhibit something called the RAF kinase within the cancer cells. RAF in turn is part of the RAS oncogene pathway. RAS is a gene which drives cell division and is over-expressed in many cancers, including RCC. More…
Celecoxib May Increase Benefit of Erlotinib for Lung Cancer
The addition of celecoxib (Celebrex) to treatment with erlotinib (Tarceva) for advanced non-small cell lung cancer (NSCLC) appears to be safe, and to increase the proportion of patients who respond to erlotinib, results of a phase I trial suggest. More…
The Latest in Non-Small Cell Lung Cancer Clinical Trials
NSCLC - Ethyol® Protects Against Side Effects of Treatment in Non-Small Cell Lung Cancer
According to results published in the International Journal of Radiation, Oncology, Biology and Physics, Ethyol® (amifostine) provides protection against side effects caused by treatment with radiation and chemotherapy, without compromising the effectiveness of therapy in patients with non-small cell lung cancer. More…
Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bortezomib may also help gemcitabine and carboplatin kill more tumor cells by making the cells more sensitive to the drugs. . More…
Phase III Randomized Study of Gemcitabine and Carboplatin Followed By Immediate Versus Delayed Docetaxel in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer. More…
NSCLC - Targeting HER1/EGFR to Improve Outcomes for Patients With Non-Small Cell Lung Cancer
- Use of Biologic Agents for Non-Small Cell Lung Cancer
- Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
- Pivotal Trial Data With Erlotinib
- Non-Small Cell Lung Cancer: The Future
- More…
NSCLC - HER1/EGFR Other Candidate Predictive and Surrogate Markers of Antitumor Activity
- Prognostic Markers for Non-Small Cell Lung Cancer: Factors Identified From Microarray
- Predictive and Surrogate Markers of Response: Statistical and Clinical Considerations
- Complex Molecular Interactions: Looking at the Model
- Target Characteristics to Define Predictive and Surrogate Markers
- Characterizing the Signaling Pathways to Determine Response
- Assessing Determinants of Resistance
- Host Characteristics to Define Predictive and Surrogate Markers
- More…
NSCLC - HER1/EGFR Can Rash Be Used as a Marker of Treatment Outcome?
- Skin-Associated Toxicity and Epidermal Growth Factor Receptor
- Rash in Phase II Studies of Epidermal Growth Factor Receptor-Targeted Agents
- Survival by Grade of Rash in Trials of Erlotinib
- Survival by Grade of Rash With Other Agents
- Severity of Rash and Pharmacokinetic Parameters
- More…
NSCLC - HER1/EGFR-Tyrosine Kinase Inhibitors: Experimental Evidence
- Properties of Erlotinib
- Erlotinib and Kinase Activation
- Experimental Data on Erlotinib
- Use of Erlotinib in Combination
- Erlotinib and Epidermal Growth Factor Receptor Variant III
- More…
NSCLC - HER1/EGFR-Tyrosine Kinase Inhibitors: Clinical Experience
- Erlotinib Phase I Monotherapy Studies
- Erlotinib Phase I Combination Studies
- Erlotinib Phase II Trial: Study Background
- Erlotinib Phase II Trial: Study Findings
- Erlotinib Phase II Trial in Bronchioloalveolar Cell Carcinoma: Study Background
- Erlotinib Phase II Trial in Bronchioloalveolar Cell Carcinoma: Study Findings
- Phase I/II Trial of Erlotinib Plus Bevacizumab: Study Background
- Phase I/II Trial of Erlotinib Plus Bevacizumab: Study Findings
- Phase III Trials in Non-Small Cell Lung Cancer
- More…
The purpose of this study is to compare the overall survival between ZD1839 (Iressa®) and docetaxel. Patients must be 18 years or over with locally advanced or metastatic recurrent non-small cell lung cancer that have previously received platinum-based chemotherapy. More…
Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer
Allos Therapeutics, Inc. today announced the initiation of a Phase 1 dose escalation study of its investigational drug PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with previously-treated (Stage IIIB-IV) advanced non-small cell lung cancer (NSCLC). More…
The Latest in Non-Small Cell Lung Cancer Protocols
NSCLC - Advanced Non-Small-Cell Lung Cancer: Focusing on the Therapeutic Horizon in 2004
Although epidermal growth factor receptor (EGFR) inhibition has not yet shown a benefit in the front-line setting in patients with advanced non-small-cell lung cancer (NSCLC), a critical, pace-setting phase 3 trial presented at the American Society of Clinical Oncology (ASCO) 2004 meeting has rejuvenated our enthusiasm. More…
Study of TLK286 vs. Gefinitib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286 is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer. More…
Randomized phase II trial to compare the effectiveness of different regimens of ZD6474 combined with docetaxel in treating patients who have locally advanced or metastaticnon-small cell lung cancer that is refractory to platinum-based chemotherapy. More…